LSE-AIM$MXCT
Maxcyte Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Maxcyte's revenue decreased due to evolving funding environment and prioritization of internal pipeline assets, impacting research and early clinical development projects.
Maxcyte reported a 6% decrease in total revenue for Q2 2023, amounting to $9.0 million compared to $9.6 million in Q2 2022. Core business revenue also declined by 14% to $8.3 million. The company signed five SPL partnerships year-to-date, bringing the total to 23. MaxCyte now expects core revenue for 2023 to be comparable to 2022 and SPL program-related revenue expectations remain unchanged at approximately $6 million for the year.
- Total revenue decreased by 6% to $9.0 million compared to Q2 2022.
- Core business revenue declined by 14% to $8.3 million compared to Q2 2022.
- Five SPL partnerships were signed year-to-date, bringing the total to 23.
- Core revenue for 2023 is expected to be comparable to 2022, with SPL program-related revenue expected at approximately $6 million.
Headline financials
Revenue & EPS history
Maxcyte · Revenue · Quarterly
$9.04M
Revenue by segment
Maxcyte · $754K total across 1 segment · Q2 2023
- Program-Related$754K+18849900.0%100.0%
Forward guidance
Core revenue for 2023 is expected to be comparable to 2022 and Strategic Platform License (“SPL”) program-related revenue expectations remain unchanged at approximately $6 million for the year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+291.3%
Avg return
Earnings day
-2.8%
Avg return
5 days after
+220.5%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+7042.3%
Q1 2025
Best reaction
-29.9%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +24.1% | +29.0% | — | |
| Q3 2025 | -12.0% | -7.2% | -12.0% | |
| Q2 2025 | -29.9% | -37.7% | -30.9% | |
| Q1 2025 | +7042.3% | -19.7% | -21.5% | |
| Q4 2024 | -8.4% | -6.1% | +5251.6% | |
| Q3 2024 | +0.5% | -7.3% | -6.7% | |
| Q2 2024 | +2.5% | -3.7% | -8.8% | |
| Q1 2024 | +0.5% | +21.2% | +23.5% | |
| Q4 2023 | +0.3% | +8.6% | +4.0% | |
| Q3 2023 | -1.5% | +2.4% | +42.6% | |
| Q2 2023 | -2.7% | -14.3% | -17.4% | |
| Q1 2023 | -0.6% | -19.2% | -2.8% | |
| Q4 2022 | +2.7% | +2.4% | +30.8% | |
| Q3 2022 | -9.4% | +3.0% | -19.9% | |
| Q2 2022 | +3.6% | +4.9% | +16.4% | |
| Q1 2022 | -4.3% | -13.0% | -12.9% | |
| Q1 2021 | -4.3% | -13.0% | -12.9% | |
| Q4 2021 | +3.4% | +6.7% | -23.7% | |
| Q4 2019 | +3.4% | +6.7% | -23.7% | |
| Q3 2020 | -7.7% | +3.8% | -9.7% | |
| Q3 2021 | -7.7% | +3.8% | -9.7% | |
| Q4 2020 | -4.1% | -6.2% | -26.3% | |
| Q2 2021 | -0.3% | -6.5% | -29.4% | |
| Q2 2020 | -0.3% | -6.5% | -29.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro